重组Anti-vascular Amyloid 1-42抗体[mOC31] - Conformation-Specific (ab201059)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [mOC31] to vascular Amyloid 1-42 - Conformation-Specific
- Suitable for: Dot blot, IHC-P, IHC-FrFl
- Reacts with: Mouse, Human
Related conjugates and formulations
概述
-
产品名称
Anti-vascular Amyloid 1-42抗体[mOC31] - Conformation-Specific
参阅全部 vascular Amyloid 1-42 一抗 -
描述
兔单克隆抗体[mOC31] to vascular Amyloid 1-42 - Conformation-Specific -
宿主
Rabbit -
经测试应用
适用于: Dot blot, IHC-P, IHC-FrFlmore details -
种属反应性
与反应: Mouse, Human -
免疫原
The details of the immunogen for this antibody are not available.
-
阳性对照
- beta Amyloid (Aß) 1-42 IHC-P: FFPE human brain Alzheimer
-
常规说明
This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
ab201059 recognizes a conformation-specific discontinuous epitope of beta Amyloid that maps to segments EFGRHSGY and ED (Hatami et al. 2014). It specifically recognizes a subset of vascular amyloid that does not colocalize with thioflavin S (Hatami et al. 2014, McLean et al. 2013).
For further information on the immunogen, please refer to Hatami et al. 2014 and Kayed et al. 2007.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
mOC31 -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab201059于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
Dot blot |
1/100.
|
|
IHC-P |
1/250 - 1/500. Do not perform antigen retrieval.
|
|
IHC-FrFl |
Use at an assay dependent concentration.
|
说明 |
---|
Dot blot
1/100. |
IHC-P
1/250 - 1/500. Do not perform antigen retrieval. |
IHC-FrFl
Use at an assay dependent concentration. |
靶标
-
别名
- A4 antibody
- A4_HUMAN antibody
- AAA antibody
see all
图片
-
Immunohistochemical staining of human brain tissue from a patient with a diagnosis of Alzheimers disease, male, 81 years, 5 hour post mortem index, tangle stage 5, plaque stage B, mini mental status exam score 12. Sections were cut using a vibratome. No antigen retrieval was performed. Free floating sections were stained using using ab201059 at a dilution of 50 ng/mL. The secondary antibody used was a biotinylated goat anti-rabbit at a dilution of 1/225, which was blocked with normal goat serum. The sample was visualized using ABC solution (1 hour incubation) followed by 1-4 minutes of DAB. The sample was mounted and allowed to dry overnight, followed by dehydration in increasingly concentrated ethanol solutions.
-
Negative control (secondary ab only):
Lane 1: beta Amyloid (Aβ) 1-40.
Lane 2: beta Amyloid (Aβ) 1-42.Primary antibody omitted.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 30 seconds. -
IHC image of beta Amyloid staining in a formalin fixed paraffin embedded human Alzheimer brain tissue section, performed on a Leica Bond™ system using the standard protocol F. No antigen retrieval was performed prior to staining. The section was incubated with ab201090 at 1/500 dilution for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Image showing staining of vascular Amyloid as described in Hatami et al. 2014
-
Dot blot analysis of beta Amyloid 1-42 labeled with ab201059 at 1/100 dilution.
Lane 1: beta Amyloid (Aβ) 1-40.
Lane 2: beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 1 minute.Antibody reactivity was assessed using a dot blot, which is a non-quantitative method that maintains the native conformation of beta Amyloid. Beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab201059:
Monomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 1% SDS and boiled for five minutes.
Oligomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils: 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20,000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.
数据表及文件
-
SDS download
-
Datasheet download
Certificate of Compliance
文献 (6)
ab201059 被引用在 6 文献中.
- Paull ML et al. A general approach for predicting protein epitopes targeted by antibody repertoires using whole proteomes. PLoS One 14:e0217668 (2019). PubMed: 31490930
- Liu TC et al. Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease. Theranostics 8:4210-4225 (2018). PubMed: 30128048
- Hatami A et al. Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-ß Peptide. J Biol Chem 292:3172-3185 (2017). PubMed: 28049728
- Hatami A et al. Monoclonal antibodies against Aß42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem 289:32131-43 (2014). PubMed: 25281743
- McLean D et al. Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-ß in TgCRND8 mice. ACS Chem Neurosci 4:613-23 (2013). PubMed: 23509918
- Heine M et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One 7:e36258 (2012). PubMed: 22590529